Antiangiogenic therapy for glioblastoma: current status and future prospects.
about
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic ReviewVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationMulti-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transitionEndothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivoLong-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/LomustineInitial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients.Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivop53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients.Characterizing nanoscale changes in the activity of VEGFR-2 on glioma microvascular endothelial cell membranes using atomic force microscopy.Molecular insights into pediatric brain tumors have the potential to transform therapy.Glioblastoma targeted therapy: updated approaches from recent biological insights.Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy.Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Glioblastoma stem cells exploit the αvβ8 integrin-TGFβ1 signaling axis to drive tumor initiation and progression.Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.Angiogenesis inhibitors in tackling recurrent glioblastoma.Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles.Disease progression patterns of bevacizumab responders with recurrent malignant gliomas.ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors.Review of Natural Product-Derived Compounds as Potent Antiglioblastoma Drugs.Differential gene expression analysis in glioblastoma cells and normal human brain cells based on GEO database.Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas.Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells.Developmentally regulated signaling pathways in glioma invasion.Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas.[Treatment of the glioma microenvironment].
P2860
Q26752321-DD22C98B-94A8-4ECD-95E7-DB29B520B571Q26781833-85152CC2-7D5F-402E-B93E-088D5DFE3918Q36032533-A6BF3D49-DEB2-4EC8-B627-0B1AAFBCAA80Q36355997-8A8D0D9B-A3E1-4710-B1E9-B37FB3DE0E5DQ36477818-5B98A984-EF26-4177-BE7D-3FD1E6E44157Q36539474-7E02DE24-B1A3-4031-8A91-D73E0383066AQ36557180-64C42D42-BB2B-4603-85D0-240F6F69C6D9Q36589454-431F51B0-9773-496E-83F1-F38C1C4DF4CBQ36665167-CBB39347-2067-4EAA-89D4-539F6B45A6C8Q37207348-3500A9ED-4FCA-48E1-82D1-F4C15FE53A37Q37468744-7973009B-A8D8-46DB-8782-E01A73EF31C6Q37536654-ED39B1E5-208A-46D1-8FC8-72AE510C19CFQ37619766-5DB1A3DC-B963-471A-A9D5-1223AE3FAC28Q37697604-BD615A51-6B69-4D62-A20B-C6C18D439789Q38268366-6C60FDA0-2F07-4079-89CF-299F2468B4A3Q38597700-527B80B5-0F2E-4F5D-907C-5CE415AC76EBQ38599484-4DC58637-5906-471A-B8F5-BCACE79754E1Q38635290-A1BE1238-B07B-4BC1-BDD2-3200CF7E01FBQ38637150-2606ED0A-7060-420D-AE22-65ABC806161AQ38706148-24092B2F-8778-4D84-B0EA-200D10176CA2Q38776701-3A899A62-4A8F-43BF-8ABB-221076FF318EQ39259089-D4598242-0FE2-4045-8345-987899B07FA9Q39755619-C4B542BD-F222-4894-B457-38723B85FCE1Q40997333-EF77E867-00A5-47CA-9F40-9ED70B3B29D7Q41325366-6C9E66DD-D0FB-43E7-B055-2950CDA7CE7EQ41616011-D8FA2986-3522-424C-B032-7A9300853757Q42906483-E42C15A4-EA8C-4057-A791-288EABC0B20BQ44888065-9D51CE6D-6974-44C0-9A4C-3557AE3C1C4EQ47099558-13181A92-E0C4-4467-A004-68206C866B89Q47100706-E689A840-180B-4131-A382-B198C7B294E4Q47638547-59DCCC76-1103-4340-B615-F27232D601DBQ48148598-C4AD1138-DDF8-46A8-B743-D7FFCD1CB8EAQ52337612-E065B9F8-53C4-413F-92A3-4E9F0A489429Q52570231-304CB14E-FCFA-4340-9BC0-ABFB20D2E611Q55384275-ED50DDF8-951D-450B-92D3-BEA564B368AFQ55460052-02092547-4A73-4C3E-AE9E-FDBA4E5A5A16
P2860
Antiangiogenic therapy for glioblastoma: current status and future prospects.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@ast
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@en
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@nl
type
label
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@ast
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@en
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@nl
prefLabel
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@ast
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@en
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@nl
P2860
P50
P1476
Antiangiogenic therapy for glioblastoma: current status and future prospects.
@en
P2093
John F de Groot
Tracy T Batchelor
P2860
P304
P356
10.1158/1078-0432.CCR-14-0834
P407
P577
2014-11-01T00:00:00Z